Quantumzyme Corp. Reports Decreased Net Loss and Increased Liabilities for Quarter Ending October 31, 2025

Quantumzyme Corp., formerly known as Reliant Services, Inc., reported its financial results for the quarter ending October 31, 2025, revealing a net loss of $49,868, a decrease from a net loss of $65,523 in the same period last year. The company did not generate any revenue during the quarter, consistent with the previous year. Operating expenses totaled $39,196, down from $60,934 in the prior year, primarily due to reduced professional fees. The company’s interest expenses increased to $10,672 from $4,589, reflecting additional debt incurred during the quarter.

As of October 31, 2025, Quantumzyme's total current assets were reported at $184, a significant decrease from $584 as of July 31, 2025. Current liabilities rose to $490,769 from $441,301, resulting in a working capital deficit of $490,585. The company’s accumulated deficit increased to $5,686,435, up from $5,636,567 at the end of the previous fiscal period. The increase in liabilities was attributed to higher accounts payable and accrued expenses, which rose to $205,573 from $175,218.

Strategically, Quantumzyme underwent significant organizational changes earlier in 2023, including a name change and the acquisition of assets from Quantumzyme Inc. This acquisition was part of a shift towards the enzyme catalyst biotransformation sector. The company issued 1,500,000 restricted shares to acquire these assets, representing approximately 73% of its outstanding shares. The management transition included the appointment of Naveen Krishna Rao Kulkarni as the sole officer and director following the resignation of Sandra Brossart.

Operationally, the company has not reported any customer counts or user statistics, and there are no indications of geographic expansion or product adoption rates in the current filing. The employee headcount remains unspecified, but the company continues to rely on external financing to support its operations. The management has expressed concerns regarding its ability to continue as a going concern, emphasizing the need for funding through securities sales or private investments to sustain operations and growth.

Looking ahead, Quantumzyme's management has indicated that while they expect operating expenses to rise due to increased business activity, there are no firm agreements in place for future financing. The company’s ability to secure necessary funding will be critical to its operational viability and growth prospects. Without sufficient capital, Quantumzyme may be forced to curtail its development plans, which could adversely affect its business and stockholder value.